Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Novo Nordisk announced the main clinical trial results of Reimagine 2. Novo Cagrisema demonstrated a weight loss effect of up to 14.2%. Cagrisema shows better weight loss effects compared to Semaglutide

Novo Nordisk announced the main clinical trial results of Reimagine 2. Novo Cagrisema demonstrated a weight loss effect of up to 14.2%. Cagrisema shows better weight loss effects compared to Semaglutide

Wallstreetcn

Feb 2, 2026 at 09:45 AM

Novo Nordisk announced the main clinical trial results of Reimagine 2.
Novo Cagrisema demonstrated a weight loss effect of up to 14.2%.
Cagrisema shows better weight loss effects compared to Semaglutide

Source: Wallstreetcn The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Related Stocks

INNOSTAR

SH688710

+9.92%

Vazyme

SH688105

+19.98%

Novo Nordisk AS

USNVO

LongbridgeAI